Evidence map›Paper›PMID 41646955›Full record

ArticleESMO gastrointestinal oncology2024

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer.

Z A Wainberg, P C Enzinger, S Qin, K Yamaguchi, J Wang, X Zhou, A Gnanasakthy, K Taylor, A Yusuf, I Majer and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03694522 (FIGHT), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03694522 phase2completednot on this map

FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1

TypeinterventionalSponsorFive Prime Therapeutics, Inc.Ran2018 to 2022Enrolled155ConditionsGastric CancerArmsBemarituzumab, Placebo, Modified FOLFOX6
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Z A WainbergDepartment of Medicine, University of California Los Angeles Medical Center, Los Angeles.
P C EnzingerDepartment of Medicine, Dana Farber Cancer Institute, Boston, USA.
S QinNanjing Tianyinshan Hospital, the 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, China.
K YamaguchiGastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan.
J WangRTI Health Solutions, Research Triangle Park, USA.
X ZhouRTI Health Solutions, Research Triangle Park, USA.
A GnanasakthyRTI Health Solutions, Research Triangle Park, USA.
K TaylorGlobal Biostatistics, Amgen Ltd., London, UK.
A YusufGlobal Medical Affairs, Amgen Inc., Thousand Oaks, USA.
I MajerGlobal HEOR, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
A JamotteGlobal HEOR, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Y-K KangAsan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in progression-free survival and overall survival relative to mFOLFOX6 alone in previously untreated locally advanced or metastatic gastric or gastroesophageal junction cancer with fibroblast growth factor receptor 2b overexpression. Using data from the final analysis, we analyzed patient-reported outcomes (PROs) to evaluate the impact of adding bemarituzumab to mFOLFOX6 on health-related quality of life (HRQoL). Materials and methods: Patients were randomized 1 : 1 to bemarituzumab plus mFOLFOX6 ( Results: PRO scale scores at baseline and compliance rates across PRO assessments over time were similar between the bemarituzumab and placebo arms. Least-squares mean changes from baseline on key EORTC QLQ-C30 scales (global health status/QoL, physical functioning, fatigue, nausea and vomiting, and appetite loss) and the EQ-5D-5L visual analog scale were similar over time between treatment arms. Analyses of time to deterioration, sustained deterioration, and improvement suggested similar HRQoL between treatment arms. Conclusions: Treatment with bemarituzumab plus mFOLFOX6 was associated with sustained HRQoL relative to mFOLFOX6 alone.

Indexed as

bemarituzumabFGFR2bgastric cancerhealth-related quality of lifemFOLFOX6targeted therapy

Identifiers

PMID41646955
PMCPMC12836807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.